DocuSign Acquires ARX

SAN FRANCISCO, March 11, 2015 /PRNewswire/ — Today, DocuSign, Inc. (DocuSign®)
announced its acquisition of Algorithmic Research, Ltd. (ARX). The acquisition builds on a three
year business partnership between DocuSign and ARX, bringing together ARX’s best-in-class
CoSign digital signature technology with the world’s leading Digital Transaction Management
(DTM) platform, to empower customers to transact business with full trust and confidence
anywhere in the world. DocuSign’s acquisition of ARX further accelerates the company’s
worldwide expansion and broadens The DocuSign Global Trust Network.

DocuSign Acquires ARX Read More »

Lithium Social Web Now Supports Instagram

SAN FRANCISCO, Feb. 12, 2015 /PRNewswire/ — Lithium Technologies announced the
addition of Instagram to Lithium Social Web (LSW), the award-winning product used by big
brands around the world to engage on social channels at scale. Instagram is the newest
addition to LSW, which already supports other social platforms, including Facebook, Twitter,
Google+, industry forums, and Lithium online communities.

Lithium Social Web Now Supports Instagram Read More »

MerLion announces FDA approval of finafloxacin otic suspension

Singapore, 11 February 2015 – MerLion Pharmaceuticals (MerLion), a biopharmaceutical company
headquartered in Singapore with clinical development operations in Berlin, Germany, today announced
that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa,
commonly known as “swimmer’s ear”, caused by Pseudomonas aeruginosa and Staphylococcus
aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in
North America for otic (ear) infections.

MerLion announces FDA approval of finafloxacin otic suspension Read More »